Psilocin

Psilocin is the active metabolite produced when the body dephosphorylates psilocybin. Aliases include 4-HO-DMT.

If psilocybin is the packaged form, psilocin is the molecule more directly tied to the acute psychedelic experience. It resembles serotonin closely enough to interact with serotonin receptors, especially the 5-HT2A receptor. That receptor activity is one reason researchers study perception, emotion, and network-level brain changes after psilocybin administration.

In pharmacology, the useful question is not whether a molecule sounds dramatic, but what it binds to, how the body handles it, and what researchers can responsibly say from human data. MicroDose IQ treats those claims conservatively: trials report outcomes in defined samples, and early research suggests mechanisms that still need replication.

Psilocin is chemically less stable than psilocybin, which is why research protocols often discuss dosing in terms of psilocybin even when the subjective effects depend on psilocin. U.S. law controls both psilocybin and psilocin, and state reforms usually mention the compounds together.

When this term appears elsewhere on the site, read it as a precision tool rather than a slogan. It helps separate chemistry from culture, research findings from personal reports, and legal status from practical risk. That distinction is especially important for U.S. readers because a term can mean one thing in a peer-reviewed trial, another in an Oregon service-center rule, and something narrower in a city decriminalization ordinance. Clear vocabulary keeps the conversation useful without turning it into advice, and it gives readers a shared baseline before they move into longer guides or state pages.

A discussion of psilocin chemistry is not a safety guarantee. Body weight, potency, preparation, other substances, and mental state can all affect a person's experience. Related terms on MicroDose IQ include psilocybin, serotonin, 5-ht2a-receptor.